Article: Acrongenomics Inc. Appoints De Facto Communications to Provide Public & Investor Relations Services.

GENEVA -- Acrongenomics Inc. (OTCBB:AGNM) announces today that it has appointed London based De Facto Communications to manage its public and investor relations from January 2008. De Facto's appointment is a key part of the strategy to finalise the development and commercialisation of the point-of-care diagnostic device that the Company is in the process of fully acquiring. De Facto's role will be to continue to build the reputation of Acrongenomics with all stakeholders in Europe and North America as the Company completes its acquisition of Molecular Vision Limited and moves towards earning its first revenues.

In November 2007, Acrongenomics Inc. announced that ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!